Feb. 8 (Bloomberg) -- Allergan Inc. fell the most in six years in New York Stock Exchange trading after U.S. regulators said the company’s wrinkle smoother Botox may be linked to cases of potentially deadly botulism. The Food and Drug Administration is evaluating reports of breathing difficulties and death after use of Botox and Solstice Neurosciences Inc.'s similar product Myobloc, according to an ``early communication’’ posted today on the agency’s Web site. Many of the most serious cases involved children who received the injections to treat arm and leg spasms associated with cerebral palsy, a use not approved by the FDA.
